BOTOX Cosmetic contains onabotulinumtoxinA, a botulinum toxin type A preparation with an extensive clinical research history in facial aesthetics. Its evidence base includes randomized, placebo-controlled studies in glabellar lines, lateral canthal lines and forehead lines. ［1–4］

Understanding this evidence requires more than looking at a single responder percentage. Study design, treatment area, assessment scale, time point, dose and comparator all influence how a result should be interpreted.

Neuronox also has published randomized, active-controlled clinical evidence. In a study of moderate-to-severe glabellar lines, the investigated Neuronox preparation met the prespecified non-inferiority criterion against onabotulinumtoxinA. ［5］

The two products should be evaluated using their respective clinical data. A study demonstrating non-inferiority for one endpoint does not establish universal interchangeability, identical duration or superiority in other treatment areas.

1. What Is BOTOX Cosmetic?

BOTOX Cosmetic is a prescription product containing onabotulinumtoxinA. It temporarily reduces activity in targeted muscles by inhibiting acetylcholine release at peripheral cholinergic nerve terminals. ［1］

The following terms are related but should not be used interchangeably:

BOTOX Cosmetic: The aesthetic product brand.

OnabotulinumtoxinA: Its active preparation.

Botulinum toxin type A: The broader toxin class.

In the United States, BOTOX Cosmetic has approved aesthetic indications that include the temporary improvement of moderate-to-severe glabellar lines, lateral canthal lines and forehead lines in adults. Approved indications and product labeling may differ in other countries. ［1］

2. Why Does Clinical Trial Design Matter?

When reading an aesthetic clinical trial, the first question should not be “What percentage of patients responded?” It should be “How was response defined?”

Six elements are especially important.

Population: Age, baseline wrinkle severity and eligibility criteria influence the generalizability of study findings.

Comparator: A placebo-controlled trial answers a different question from an active-controlled trial.

Treatment area: Glabellar-line findings do not automatically apply to forehead or lateral canthal lines.

Dose: Findings apply to the studied preparation and protocol.

Endpoint: A one-grade improvement is different from a two-grade composite response.

Time point: Day 30 response and Day 120 response describe different stages of treatment effect.

These distinctions help explain why two credible studies can report different responder rates without contradicting each other.

3. Evidence in Glabellar Lines

3.1 Carruthers et al.: A Randomized, Placebo-Controlled Trial

Carruthers and colleagues conducted a multicenter, double-blind, randomized, placebo-controlled study involving 264 participants with moderate-to-severe glabellar lines. Of these, 203 were assigned to BOTOX 20 U and 61 to placebo. Participants were followed for 120 days. ［2］

The investigators assessed glabellar-line severity at maximum frown and at rest, patient-reported improvement and adverse events.

The BOTOX group showed significantly greater reductions in glabellar-line severity than the placebo group at follow-up assessments. The study also reported that many participants maintained an effect through Day 120. ［2］

Clinical interpretation: This trial supports efficacy against placebo for the studied glabellar-line protocol. It does not establish superiority over another active botulinum toxin product.

3.2 What Does the Prescribing Information Report?

The U.S. BOTOX Cosmetic prescribing information summarizes pooled results from two randomized, double-blind, placebo-controlled glabellar-line studies. ［1］

For the investigator-assessed endpoint of none or mild glabellar-line severity at maximum frown, the reported responder rates were as follows.

Day 7: BOTOX Cosmetic 74% (299/405), compared with placebo 6% (8/132).

Day 30: BOTOX Cosmetic 80% (325/405), compared with placebo 3% (4/132).

Day 60: BOTOX Cosmetic 70% (283/403), compared with placebo 2% (2/130).

Day 90: BOTOX Cosmetic 48% (192/403), compared with placebo 2% (3/128).

Day 120: BOTOX Cosmetic 25% (102/403), compared with placebo 2% (2/128).

The Day 30 comparison was a co-primary efficacy assessment and was statistically significant. ［1］

What these numbers mean: The percentage of participants meeting the defined response criterion decreased over time. A Day 120 responder rate of 25% does not mean that the other 75% experienced no remaining effect; it means they did not meet that particular response threshold at that assessment.

3.3 Investigator and Patient Assessments Are Not Identical

The same prescribing information reports a separate patient-assessed endpoint: at least moderate improvement in the appearance of glabellar lines. ［1］

At Day 30, the patient-assessed responder rate was 89% with BOTOX Cosmetic versus 7% with placebo. At Day 120, the corresponding rates were 39% and 1%. ［1］

The investigator and patient percentages differ because they measure different outcomes. Neither should be substituted for the other without explaining the endpoint.

4. Evidence in Lateral Canthal Lines

Lateral canthal lines are the wrinkles commonly described as crow’s feet.

The U.S. prescribing information includes two randomized, double-blind, placebo-controlled studies evaluating BOTOX Cosmetic for moderate-to-severe lateral canthal lines. ［1］

The studies used specific investigator and participant assessments to evaluate treatment response. Some study arms also assessed simultaneous treatment of lateral canthal and glabellar lines.

These data support conclusions about the investigated treatment areas and protocols. They should not be combined indiscriminately with glabellar-line response rates because the facial anatomy and endpoints differ.

5. Evidence in Forehead Lines

Forehead lines involve the frontalis muscle and require consideration of eyebrow position and the interaction between the forehead and glabellar muscle groups.

The U.S. prescribing information describes two multicenter, randomized, double-blind, placebo-controlled studies of BOTOX Cosmetic for moderate-to-severe forehead lines. Both studies assessed forehead and glabellar-line treatment; one also evaluated lateral canthal-line treatment. ［1］

Phase III Evidence in Upper Facial Lines

In a published Phase III study, 787 participants were included in the intent-to-treat population. Participants were randomized to onabotulinumtoxinA 40 U, onabotulinumtoxinA 64 U or placebo under the study's upper-face treatment protocols. ［4］

At Day 30, the proportions achieving at least a two-grade improvement in forehead-line severity on both investigator and participant Facial Wrinkle Scale assessments were as follows.

OnabotulinumtoxinA 40 U: 45.6%.

OnabotulinumtoxinA 64 U: 53.0%.

Placebo: 0.6%.

Both active-treatment groups differed significantly from placebo. ［4］

Clinical interpretation: These results support efficacy for the studied upper-face protocols. They are not directly comparable with the glabellar-line percentages above because the treatment areas and response definitions differ.

6. How Should Duration Be Interpreted?

Duration is one of the most frequently misunderstood outcomes in botulinum toxin research.

A study may report the time until the first observable response, the percentage of participants responding at a particular visit, median duration of response, time until participants return to a specified wrinkle-severity grade, or patient-reported persistence of improvement.

These are related but distinct measures.

For example, the pooled BOTOX Cosmetic glabellar-line studies reported an investigator-assessed responder rate of 80% at Day 30 and 25% at Day 120. ［1］

That describes how many participants met a defined threshold at each time point. It is not equivalent to measuring the precise duration of effect in every participant.

Similarly, a trial reporting a median duration does not imply that every patient will experience that duration.

A claim that one brand lasts longer than another requires an appropriately designed comparison with compatible endpoints.

7. What Does the Evidence Show About Safety?

Safety evaluation is an essential part of aesthetic clinical research.

The original randomized glabellar-line study by Carruthers and colleagues reported mostly mild blepharoptosis in 5.4% of the BOTOX-treated group. ［2］

The U.S. prescribing information also lists adverse reactions observed in its clinical studies and includes a boxed warning concerning the potential distant spread of toxin effect. ［1］

The safety profile should be interpreted in the context of the specific product and approved indication, the patient's medical history and relevant contraindications, concomitant medications, the treatment area and administration technique, and the adverse-event definitions and follow-up period used in a study.

A low adverse-event rate in one study does not establish that a product is safer than another product investigated in a different population.

8. What Does BOTOX Cosmetic Evidence Tell Us About Neuronox?

BOTOX Cosmetic is an important active comparator in botulinum toxin clinical research.

However, evidence from a BOTOX Cosmetic trial cannot simply be transferred to Neuronox. Neuronox must be evaluated using its own product-specific studies.

8.1 Direct Comparative Evidence in Glabellar Lines

Won and colleagues conducted a randomized, double-blind, active-controlled Phase III study involving 314 randomized participants with moderate-to-severe glabellar lines. The study compared the investigated Neuronox preparation with onabotulinumtoxinA. ［5］

The primary endpoint was the investigator-assessed responder rate at maximum frown at Week 4.

Studied Neuronox preparation: 93.7% (133/142) responder rate at Week 4.

OnabotulinumtoxinA: 94.5% (138/146) responder rate at Week 4.

The study met its prespecified non-inferiority criterion. The investigators also reported no significant between-group differences in the assessed secondary efficacy endpoints. ［5］

Why this matters for Neuronox: Its glabellar-line evidence includes a randomized comparison against an active botulinum toxin product, rather than relying only on placebo-controlled evidence or indirect comparisons.

8.2 What Non-Inferiority Does—and Does Not—Mean

A non-inferiority trial tests whether a treatment's efficacy is not worse than the comparator by more than a prespecified acceptable margin.

For the Won et al. study, the finding supports non-inferiority of the investigated Neuronox preparation for the specified Week 4 glabellar-line endpoint. ［5］

It does not independently establish superior efficacy of Neuronox, identical clinical outcomes in every patient, equal duration in every treatment area, universal unit interchangeability, or efficacy in indications not evaluated by the study.

The appropriate evidence-based message is that Neuronox has published direct comparative clinical data supporting its studied aesthetic use.

9. Why Cross-Trial Percentages Can Be Misleading

Consider two findings discussed in this article.

BOTOX Cosmetic: 80% investigator-assessed response at Day 30 in pooled placebo-controlled glabellar-line studies. ［1］

Studied Neuronox preparation: 93.7% investigator-assessed response at Week 4 in an active-controlled glabellar-line trial. ［5］

These percentages should not be used to conclude that Neuronox has a higher response rate than BOTOX Cosmetic.

The studies differ in design, participant selection, endpoint definitions and analysis populations. In addition, the Neuronox trial included its own onabotulinumtoxinA comparison group, which reported a 94.5% response under the same study protocol. ［5］

The appropriate comparison is the randomized, within-study comparison—not a comparison of percentages taken from unrelated trials.

10. A Practical Framework for Reading Aesthetic Evidence

Before using a clinical study to support a product statement, check the following questions.

Was the study randomized? Verify whether treatment assignment reduced selection bias.

Was it blinded? Determine whether participants and assessors knew the treatment assignment.

What was the comparator? Identify whether the study used placebo, an active product or no comparator.

What was the primary endpoint? Check the exact response definition and assessment time.

Was the result statistically supported? Review the prespecified hypothesis, margin and reported analysis.

Which product was studied? Confirm the brand, preparation and applicable formulation.

What can be claimed? Limit conclusions to those supported by the studied population, indication and endpoint.

This framework is particularly important when developing educational or promotional content about botulinum toxin products.

Frequently Asked Questions

Does BOTOX Cosmetic have randomized clinical evidence?

Yes. Its clinical evidence includes randomized, placebo-controlled studies in glabellar lines, lateral canthal lines and forehead lines. ［1–4］

Does an 80% response rate mean 80% of patients have the same result?

No. It means 80% met the specific investigator-assessed response definition at the reported time point in the pooled glabellar-line studies. ［1］

Does BOTOX Cosmetic last exactly four months?

No. Its glabellar-line trials reported responses through Day 120 in some participants, but the duration of effect varies. ［1,2］

Are forehead-line and glabellar-line response rates directly comparable?

Not necessarily. They involve different treatment areas and may use different protocols or endpoints. ［1,4］

Has Neuronox been compared directly with onabotulinumtoxinA?

Yes. A randomized, double-blind, active-controlled study in moderate-to-severe glabellar lines reported that the investigated Neuronox preparation met its prespecified non-inferiority criterion. ［5］

Does that mean Neuronox and BOTOX Cosmetic are interchangeable?

No. Non-inferiority for a specified clinical endpoint does not establish universal interchangeability or a conversion rule between products.

Conclusion

BOTOX Cosmetic has an established clinical evidence base in facial aesthetics, including randomized studies in glabellar, lateral canthal and forehead lines. Its trial results illustrate why efficacy must be interpreted according to the treatment area, comparator, endpoint and follow-up period. ［1–4］

Neuronox also has product-specific randomized comparative evidence. In a published glabellar-line study, the investigated Neuronox preparation met the prespecified non-inferiority criterion against onabotulinumtoxinA. ［5］

For BotoxWiki, the central evidence-based message is that both products should be described through their own clinical findings. Accurate communication distinguishes what a trial demonstrates from broader claims that the trial was not designed to establish.

References

［1］ AbbVie Inc. BOTOX Cosmetic (onabotulinumtoxinA): U.S. Prescribing Information. DailyMed. Verify the current locally approved revision before publication.

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab

［2］ Carruthers JA, Lowe NJ, Menter MA, et al.; BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840–849. doi:10.1067/mjd.2002.121356.

https://pubmed.ncbi.nlm.nih.gov/12063480/

［3］ Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112(4):1089–1098. doi:10.1097/01.PRS.0000076504.79727.62.

https://pubmed.ncbi.nlm.nih.gov/12973229/

［4］ Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines. PMID:30096106. Complete author and bibliographic details should be checked before publication.

https://pubmed.ncbi.nlm.nih.gov/30096106/

［5］ Won CH, Lee HM, Lee WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072.

https://pubmed.ncbi.nlm.nih.gov/23301821/

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.